Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by:
Translational Oncology Research International
ClinicalTrials.gov Identifier:
NCT00095706
First received: November 5, 2004
Last updated: September 23, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2012
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)